Department of Internal Medicine, College of Oriental Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-Ku, Seoul 130-702, Republic of Korea.
Phytother Res. 2010 Dec;24(12):1886-92. doi: 10.1002/ptr.3347. Epub 2010 Oct 29.
Chronic kidney disease (CKD) is a common cause of end-stage renal disease. Antihypertensive agents are used clinically to inhibit the progression of CKD, but cannot prevent eventual renal failure. This study investigated the effect of Tanshinone IIA, an active component of Salvia miltiorrhiza, in rats suffering from CKD induced by 5/6 nephrectomy. After development of renal insufficiency, the rats were treated with Tanshinone IIA (10 mg/kg) for 8 weeks. Serum creatinine, angiotensin II (Ang II), transforming growth factor β1 (TGF-β1) and collagen IV levels were significantly reduced in Tanshinone IIA treated rats compared with a control group. In addition, Tanshinone IIA suppressed increases in urinary protein excretion in CKD rats. These findings suggest that chronic oral administration of Tanshinone IIA can improve renal dysfunction associated with CKD.
慢性肾脏病（CKD）是终末期肾病的常见病因。临床上使用抗高血压药物来抑制 CKD 的进展，但不能防止最终的肾衰竭。本研究探讨了丹参酮 IIA（丹参的一种活性成分）在 5/6 肾切除诱导的 CKD 大鼠中的作用。在肾功能不全发展后，用丹参酮 IIA（10mg/kg）治疗大鼠 8 周。与对照组相比，丹参酮 IIA 治疗组大鼠的血清肌酐、血管紧张素 II（Ang II）、转化生长因子-β1（TGF-β1）和胶原 IV 水平显著降低。此外，丹参酮 IIA 抑制 CKD 大鼠尿蛋白排泄增加。这些发现表明，慢性口服丹参酮 IIA 可改善与 CKD 相关的肾功能障碍。
